BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9383576)

  • 1. Oligonucleotide therapeutics for human leukaemia.
    Gewirtz AM
    Ciba Found Symp; 1997; 209():169-91; discussion 191-4. PubMed ID: 9383576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myb targeted therapeutics for the treatment of human malignancies.
    Gewirtz AM
    Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of an anti-c-myb antisense oligonucleotide on myo-intimal proliferation. Specificity of action and consequences on vasoreactivity].
    Castier Y; Chemla E; Chardigny C; Nierat J; Eudes D; Vasseur MA; Bruneval P; Carpentier A; Fabiani JN
    Arch Mal Coeur Vaiss; 1996 Jul; 89(7):889-96. PubMed ID: 8869251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotide therapeutics for human leukemia.
    Gewirtz AM
    Crit Rev Oncog; 1997; 8(1):93-109. PubMed ID: 9516088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic intervention in glomerulonephritis by oligonucleotides.
    Kashihara N; Maeshima Y; Makino H
    Exp Nephrol; 1997; 5(2):126-31. PubMed ID: 9108994
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide therapeutics for human leukemia.
    Gewirtz AM
    Curr Opin Hematol; 1998 Jan; 5(1):59-71. PubMed ID: 9515205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense strategies in the treatment of leukemias.
    Calabretta B; Skorski T; Ratajczak MZ; Gewirtz AM
    Semin Oncol; 1996 Feb; 23(1):78-87. PubMed ID: 8607034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications.
    Gewirtz AM
    Mt Sinai J Med; 1996; 63(5-6):372-80. PubMed ID: 8898543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of C-myb in human metastatic melanoma cell lines and specimens.
    Walker MJ; Silliman E; Dayton MA; Lang JC
    Anticancer Res; 1998; 18(2A):1129-35. PubMed ID: 9615777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The c-myb proto-oncogene: a novel target for human gene therapy.
    Gewirtz AM
    Cancer Treat Res; 1996; 84():93-112. PubMed ID: 8724627
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin.
    Funato T; Satou J; Kozawa K; Fujimaki S; Miura T; Kaku M
    Oncol Rep; 2001; 8(4):807-10. PubMed ID: 11410788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology evaluation: leukemia therapy, University of Pennsylvania.
    Orr RM
    Curr Opin Mol Ther; 1999 Jun; 1(3):399-403. PubMed ID: 11713805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins.
    Rushton JJ; Davis LM; Lei W; Mo X; Leutz A; Ness SA
    Oncogene; 2003 Jan; 22(2):308-13. PubMed ID: 12527900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.